Generalizability of the results of efficacy trials in first-episode schizophrenia: Comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST)

Journal of Clinical Psychiatry

Volumn 71, Issue 1, 2010, Pages 58-65

  Boter, Han ^a   Derks, Eske M ^a   Fleischhacker, W Wolfgang ^b   Davidson, M ^c   Kahn, René S ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIFORM DISORDER; SOCIAL PSYCHOLOGY; SUBSTANCE ABUSE; SUICIDE; ADDICTION; AGE; COMPARATIVE STUDY; MULTICENTER STUDY; PATIENT COMPLIANCE; PATIENT SELECTION; PSYCHOLOGICAL ASPECT; SCHIZOPHRENIA; SEX DIFFERENCE; SUICIDE ATTEMPT;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; PATIENT COMPLIANCE; PATIENT SELECTION; SCHIZOPHRENIA; SEX FACTORS; SUBSTANCE-RELATED DISORDERS; SUICIDE, ATTEMPTED;

EID: 77449133585     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04506yel     Document Type: Article

References (27)

1. Leucht S, Heres S, Hamann J, et al. Methodological issues in current antipsychotic drug trials. Schizophr Bull. 2008;34(2):275-285.
2. Fleischhacker WW, Keet IP, Kahn RS. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr Res. 2005;78(2):147-156.
3. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618): 1085-1097.
4. Fleischhacker WW, Hummer M. Do phase III trials have clinical value? J Clin Psychopharmacol. 1999;19(5):391-392.
5. Stroup TS, Alves WM, Hamer RM, et al. Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nat Rev Drug Discov. 2006;5(2):133-146.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC. American Psychiatric Association; 1994.
7. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33.
8. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
9. Guy W. Clinical Global Impressions (CGI) Scale. In: Rush AJ Jr, Pincus HA, First MB, et al, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000:100-102.
10. Jones SH, Thornicroft G, Coffey M, et al. A brief mental health outcome scale - reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry. 1995;166(5):654-659.
11. Addington D, Addington J, Maticka-Tyndale E, et al. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res. 1992;6(3):201-208.
12. Priebe S, Huxley P, Knight S, et al. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int J Soc Psychiatry. 1999;45(1):7-12.
13. Gerlach J, Korsgaard S, Clemmesen P, et al. The St Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand. 1993;87(4):244-252.
14. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;76(334):1-100.
15. Phelan M, Slade M, Thornicroft G, et al. The Camberwell Assessment of Need: the validity and reliability of an instrument to assess the needs of people with severe mental illness. Br J Psychiatry. 1995;167(5):589-595.
16. Kemp R, Hayward P, Applewhaite G, et al. Compliance therapy in psychotic patients: randomised controlled trial. BMJ. 1996;312(7027):345-349.
17. Muthén BO, Curran PJ. General longitudinal modeling of individual differences in experimental designs: a latent variable framework for analysis and power estimation. Psychol Methods. 1997;2(4):371-402.
18. Melle I, Johannesen JO, Friis S, et al. Early detection of the first episode of schizophrenia and suicidal behavior. Am J Psychiatry. 2006;163(5): 800-804.
19. Nordentoft M, Jeppesen P, Abel M, et al. OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis: One-year follow-up of a randomised controlled trial. Br J Psychiatry Suppl. 2002;181(43):s98-s106.
20. Rabinowitz J, Bromet EJ, Davidson M. Are patients enrolled in first episode psychosis drug trials representative of patients treated in routine clinical practice? Schizophr Res. 2003;61(2-3):149-155.
21. Lambert M, Conus P, Lubman DI, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand. 2005;112(2):141-148.
22. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994;51(4):273-279.
23. Van Mastrigt S, Addington J, Addington D. Substance misuse at presentation to an early psychosis program. Soc Psychiatry Psychiatr Epidemiol. 2004;39(1):69-72.
24. Addington J, Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr Scand. 2007;115(4):304-309.
25. Archie S, Rush BR, Akhtar-Danesh N, et al. Substance use and abuse in first-episode psychosis: prevalence before and after early intervention. Schizophr Bull. 2007;33(6):1354-1363.
26. Verdoux H, Liraud F, Gonzales B, et al. Suicidality and substance misuse in first-admitted subjects with psychotic disorder. Acta Psychiatr Scand. 1999;100(5):389-395.
27. Hides L, Dawe S, Kavanagh DJ, et al. Psychotic symptom and cannabis relapse in recent-onset psychosis. prospective study. Br J Psychiatry. 2006;189:137-143.